Skip to main content

Advertisement

SpringerLink
Log in

Effects of crocin on inflammatory activities in human fibroblast-like synoviocytes and collagen-induced arthritis in mice

  • Original Article
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease, characterized by the irreversible joint destruction resulted from the attack of inflammatory cells to the joints. Recent studies demonstrated that crocin is able to alleviate arthritis and suppress inflammatory responses, implying crocin as a potential promising antiarthritic agent. In this study, we confirmed the effect of crocin on RA and revealed its underlying mechanism by measuring lipopolysaccharides (LPS)-stimulated cytokine production in presence or absence of crocin. The effect of crocin was also tested in vivo using a mouse model of collagen-induced arthritis (CIA). It was found that crocin significantly repressed the LPS-induced expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in human fibroblast-like synoviocytes (FLS). We tested the effect of crocin on nuclear factor-kappa B (NF-κB) signaling and observed that cells pre-treated with 500 μM of crocin exhibited lower levels of LPS-induced p-IκBα, p-IκB kinase (IKK) α/β, and p65 expression than those of untreated cells. In addition, we found when cells were stimulated with IKKβ, crocin pre-treatment showed significantly inhibitory effect on the luciferase activity of IL-1β. In vivo results also showed that crocin treatment dramatically reduced plasma levels of TNF-α, IL-1β, and IL-6 in CIA mice. Crocin is efficient to suppress the productions of TNF-α, IL-6, and IL-1β by blocking NF-κB signal activation through its interaction with IKK, suggesting that crocin could be an efficient treatment for RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339:166–72.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2009;48:1309–13. https://doi.org/10.1093/rheumatology/kep252.

    Article  Google Scholar 

  3. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–7. https://doi.org/10.1002/art.24092.

    Article  PubMed  Google Scholar 

  4. Ajeganova S, van Steenbergen HW, van Nies JA, Burgers LE, Huizinga TW, van der Helm-van Mil AH. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016;75:867–73. https://doi.org/10.1136/annrheumdis-2014-207080.

    Article  PubMed  CAS  Google Scholar 

  5. Emery P, Keystone E, Tony H, Cantagrel A, Van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of Japanese rheumatoid arthritis patients for longterm safety. J Rheumatol. 2011;38:1258–64. https://doi.org/10.3899/jrheum.101009.

    Article  PubMed  CAS  Google Scholar 

  7. Yamamoto Y, Gaynor RB. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci. 2004;29:72–9.

    Article  PubMed  CAS  Google Scholar 

  8. Israël A. The IKK complex, a central regulator of NF-κB activation. Cold Spring Harb Perspect Biol. 2010;2:a000158.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Gilston V, Jones HW, Soo CC, Coumbe A, Blades S, Kaltschmidt C, et al. NF-kappa B activation in human knee-joint synovial tissue during the early stage of joint inflammation. Biochem Soc Trans. 1997;518S:25.

    Google Scholar 

  10. Roman-Blas J, Jimenez S. NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2006;14:839–48.

    Article  PubMed  CAS  Google Scholar 

  11. Makarov SS. NF-κB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res Ther. 2001;3:200.

    Article  CAS  Google Scholar 

  12. Nam KN, Park YM, Jung HJ, Lee JY, Min BD, Park SU, et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol. 2010;648:110–6. https://doi.org/10.1016/j.ejphar.2010.09.003.

    Article  PubMed  CAS  Google Scholar 

  13. Yarijani ZM, Pourmotabbed A, Pourmotabbed T, Najafi H. Crocin has anti-inflammatory and protective effects in ischemia-reperfusion induced renal injuries. Iran J Basic Med Sci. 2017;20:753.

    PubMed  PubMed Central  Google Scholar 

  14. Ding Q, Zhong H, Qi Y, Cheng Y, Li W, Yan S, et al. Anti-arthritic effects of crocin in interleukin-1beta-treated articular chondrocytes and cartilage in a rabbit osteoarthritic model. Inflamm Res. 2013;62:17–25. https://doi.org/10.1007/s00011-012-0546-3.

    Article  PubMed  CAS  Google Scholar 

  15. Li X, Jiang C, Zhu W. Crocin reduces the inflammation response in rheumatoid arthritis. Biosci Biotechnol Biochem. 2017;81:891–8. https://doi.org/10.1080/09168451.2016.1263145.

    Article  PubMed  CAS  Google Scholar 

  16. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473–88. https://doi.org/10.1038/nrd1109.

    Article  PubMed  CAS  Google Scholar 

  17. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74. https://doi.org/10.1016/S0140-6736(07)60784-3.

    Article  PubMed  CAS  Google Scholar 

  18. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1:102–10. https://doi.org/10.1038/ncprheum0047.

    Article  PubMed  CAS  Google Scholar 

  19. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163–96.

    Article  PubMed  CAS  Google Scholar 

  20. Maini R, Taylor P. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000;51:207–29.

    Article  PubMed  CAS  Google Scholar 

  21. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443–50. https://doi.org/10.1002/art.10308.

    Article  PubMed  CAS  Google Scholar 

  22. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheumatol. 2004;50:3432–43.

    Article  CAS  Google Scholar 

  23. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven RV, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheumatol. 2006;54:26–37.

    Article  CAS  Google Scholar 

  24. Lv B, Huo F, Zhu Z, Xu Z, Dang X, Chen T, et al. Crocin upregulates CX3CR1 expression by suppressing NF-kappaB/YY1 signaling and inhibiting lipopolysaccharide-induced microglial activation. Neurochem Res. 2016;41:1949–57. https://doi.org/10.1007/s11064-016-1905-1.

    Article  PubMed  CAS  Google Scholar 

  25. Du J, Chi Y, Song Z, Di Q, Mai Z, Shi J, et al. Crocin reduces aspergillus fumigatus-induced airway inflammation and NF-kappaB signal activation. J Cell Biochem. 2017;119:1746–54. https://doi.org/10.1002/jcb.26335.

    Article  PubMed  CAS  Google Scholar 

  26. Li S, Liu X, Lei J, Yang J, Tian P, Gao Y. Crocin protects podocytes against oxidative stress and inflammation induced by high glucose through inhibition of NF-κB. Cell Physiol Biochem. 2017;42:1481–92.

    Article  PubMed  CAS  Google Scholar 

  27. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O, Bresnihan B. Increased synovial tissue NF-κB1 expression at sites adjacent to the cartilage–pannus junction in rheumatoid arthritis. Arthritis Rheumatol. 2004;50:1781–7.

    Article  CAS  Google Scholar 

  28. Carlsen H, Moskaug JØ, Fromm SH, Blomhoff R. In vivo imaging of NF-κB activity. J Immunol. 2002;168:1441–6.

    Article  PubMed  CAS  Google Scholar 

  29. Handel ML, Mcmorrow LB, Gravallese EM. Nuclear factor–kB in rheumatoid synovium. Localization of P50 and P65. Arthritis Rheumatol. 1995;38:1762–70.

    Article  CAS  Google Scholar 

  30. Fu L, Pan F, Jiao Y. Crocin inhibits RANKL-induced osteoclast formation and bone resorption by suppressing NF-κB signaling pathway activation. Immunobiology. 2017;222:597–603.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Sports Medicine, The Cangzhou City Central Hospital, 16 Xinhua Road, Yunhe Region, Cangzhou City, 061001, Hebei Province, China

    Longjie Li, Haiseng Zhang & Chang Liu

  2. Department of Orthopedics, The Cangzhou City Central Hospital, 16 Xinhua Road, Yunhe Region, Cangzhou City, 061001, Hebei Province, China

    Shengli Jin

Authors
  1. Longjie Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haiseng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengli Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chang Liu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Informed consent

Informed consent is not applicable in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, L., Zhang, H., Jin, S. et al. Effects of crocin on inflammatory activities in human fibroblast-like synoviocytes and collagen-induced arthritis in mice. Immunol Res 66, 406–413 (2018). https://doi.org/10.1007/s12026-018-8999-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-018-8999-2

Keywords

Search

Navigation